| Name | U-104 |
| Description | U-104 (NSC-213841) is an effective carbonic anhydrase (CA) inhibitor for CA IX( Ki=45.1 nM) and CA XII(Ki=4.5 nM). |
| Kinase Assay | Kinase assay: Calu-6 cells are cultured in MEM containing 10% fetal bovine serum and 1% penicillin/streptomycin and plated 1 day before the start of the experiment at 1 × 104 cells per well in a 384-well plate. Proteasome activity is assessed by monitoring hydrolysis of the chymotrypsin-like substrate Suc-LLVY-aminoluciferin in the presence of luciferase using the Proteasome-Glo assay reagents according to the manufacturer's instructions. Luminescence is measured using a LEADseeker instrument. |
| In vitro | UNC1215 increased cell mobility and point mutations of the GFP-L3MBTL3 fusion protein, interfered with the Kme-binding function of the GFP-L3MBTL3 phenotypic mimic, and affected the localization of UNC1215.UNC1215 (30 μM) did not affect the tandem Tudor domain of UHRF1, the chromatin domain of CBX7, and the PHD domain of JARID1A. In MCF7,22RV1 and IMR90 cells, UNC0631 significantly reduced H3K9me2 levels. Brimonidine (0.5/1 mg/kg) reduced progressive ganglion cell loss (26%/15%). |
| In vivo | UNC1215 increased cell mobility and point mutations of the GFP-L3MBTL3 fusion protein, interfered with the Kme-binding function of the GFP-L3MBTL3 phenotypic mimic, and affected the localization of UNC1215.UNC1215 (30 μM) did not affect the tandem Tudor domain of UHRF1, the chromatin domain of CBX7, and the PHD domain of JARID1A. In MCF7,22RV1 and IMR90 cells, UNC0631 significantly reduced H3K9me2 levels. Brimonidine (0.5/1 mg/kg) reduced progressive ganglion cell loss (26%/15%). |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 40 mg/mL (129.32 mM), Sonication is recommended.
|
| Keywords | LM2-4 | NSC213841 | CAIX | CAI | CAXII | U-104 | exosome | SLC-0111 | SLC0111 | Carbonate dehydratase | NSC 213841 | Carbonic Anhydrase | U104 | inhibit | SLC 0111 | 4T1 | U 104 | Inhibitor | CAII | MST104 | MST 104 |
| Inhibitors Related | Benzenesulfonamide | Urea | Topiramate | Cyclamic acid sodium | Ellagic acid | Orthanilamide | Tioxolone | Zonisamide | Histone acetyltransferase p300 Inhibitor 4c | EMAC10101d | pNNP | Trichlormethiazide |
| Related Compound Libraries | Bioactive Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Clinical Compound Library | Bioactive Compounds Library Max | Covalent Inhibitor Library | Anti-Cancer Compound Library | Anti-Cancer Drug Library | Anti-Cancer Active Compound Library |
United States
